Recent studies showed that aberrantly increased expression of interleukin-17A (IL-17A) and β-catenin are closely associated with GCTB progression, including tumor growth, bone destruction, and recurrence.3, 4 However, the regulatory mechanism of IL-17A and β-catenin in GCTB is not fully understood. The gene discussed is IL17A; the disease is neoplasm.